<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333759</url>
  </required_header>
  <id_info>
    <org_study_id>20170490</org_study_id>
    <nct_id>NCT03333759</nct_id>
  </id_info>
  <brief_title>Treatment of Acne Scars With Erbium:Yttrium Aluminum Garnet (Er:YAG) Laser Examined Under OCT</brief_title>
  <official_title>Treatment of Atrophic Facial Acne Scars With Er:YAG Laser Examined Under Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is examining the effects of the 2940 nm Er:YAG on atrophic facial acne scars under
      optical coherence tomography in terms of blood flow, vessel shape, skin roughness, collagen
      content, and epidermal thickness.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood flow</measure>
    <time_frame>During 8 weeks</time_frame>
    <description>Optical coherence tomography (OCT) will be used to quantitatively measure changes in facial atrophic acne scars in terms of blood flow (proportion of signals with strong dynamic signal (%)/depth (mm)).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in epidermal thickness</measure>
    <time_frame>During 8 weeks</time_frame>
    <description>Optical coherence tomography (OCT) will be used to quantitatively measure changes in facial atrophic acne scars in terms of epidermal thickness (mm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in collagen content</measure>
    <time_frame>During 8 weeks</time_frame>
    <description>OCT will be used to qualitatively measure changes in facial atrophic acne scars in terms of collagen content. Collagen content will be measured in terms of brightness of OCT scan. Areas of skin that contain collagen tend to be brighter (more white in color) whereas areas with less collagen content tend to be darker.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in skin roughness</measure>
    <time_frame>During 8 weeks</time_frame>
    <description>OCT will be used to quantitatively measure changes in facial atrophic acne scars in terms of skin roughness (Âµm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Patient Scar Assessment Scale</measure>
    <time_frame>During 8 weeks</time_frame>
    <description>Scale (1-10) used to qualitatively monitor treatment and changes in scars by the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Observer Scar Assessment Scale</measure>
    <time_frame>During 8 weeks</time_frame>
    <description>Scale (1-10) used to qualitatively monitor treatment and changes in scars by the dermatologist.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Laser Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive one laser treatment (week 0) with the Erbium YAG laser at a 2940nm wavelength (Alma - Harmony XL Laser) and parameters corresponding with their acne scar severity. They will then return to the clinic 1, 4 and 8 weeks (7, 30, and 56 days + 7 days) after the treatment for their scars to be evaluated under optical coherence tomography.
Laser parameters are as follows:
iPixelEr 2940nm Erbium:YAG Module: mild scars: 7 by 7 (7X7) mm tip, energy 1400-1600 millijoules/P (mJ), pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap moderate scars: 7X7 mm tip, energy 1600-1800 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap severe scars: 7X7 mm tip, 1800-2000 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alma - Harmony XL Laser</intervention_name>
    <description>The Erbium YAG laser at a 2940nm wavelength is used for ablative laser resurfacing as well as treating acne scars.</description>
    <arm_group_label>Laser Treatment</arm_group_label>
    <other_name>Modified Alma Laser Harmony Neodymium-Doped Yttrium Aluminium Garnet (Nd:YAG) Module</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients should be 18-90 years of age

          2. Patients should have Fitzpatrick skin types of I-III

          3. Patients should have at least mild acne

        Exclusion Criteria:

          1. The patient should not be receiving any additional systemic, topical, or intralesional
             treatment of the scars during the study

          2. Pregnant or lactating females

          3. Fitzpatrick skin type of IV-VI

          4. A history of keloids or hypertrophic scars

          5. Scleroderma

          6. Photosensitivity

          7. Botulinum toxin injection, facial laser resurfacing, chemical peels, fillers, or usage
             of oral retinoid within the last 6 months

          8. Subjects with a known history of herpes simplex
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keyvan Nouri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcela Salgado</last_name>
    <phone>3052438485</phone>
    <email>MSalgado@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ali Rajabiestarabadi, MD</last_name>
    <phone>3052439443</phone>
    <email>arajabi@med.miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keyvan Nouri, MD</last_name>
      <phone>305-243-3380</phone>
      <email>KNouri@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Keyvan Nouri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali Rajabiestarabadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Keyvan Nouri</investigator_full_name>
    <investigator_title>Doctor of Medicine</investigator_title>
  </responsible_party>
  <keyword>laser</keyword>
  <keyword>Er:YAG laser</keyword>
  <keyword>acne</keyword>
  <keyword>acne vulgaris</keyword>
  <keyword>optical coherence tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

